OBJECTIVE: Our aim was to determine the efficacy and toxicity of paclitaxel in the treatment of refractory and platinum-resistant epithelial ovarian cancer. STUDY DESIGN: Eligibility required three prior failed chemotherapy regimens and documented platinum resistance. One hundred patients with advanced ovarian cancer received paclitaxel 135 mg/m2 over 24 hours every 21 days with optional granulocyte colony-stimulating factor support. RESULTS: Paclitaxel was generally well tolerated. In four patients bowel perforation or fistula developed. After three cycles 34% of patients had stable disease and 25% of patients demonstrated a response, either partial or complete. After six cycles 24% of patients continued to respond. To date, six patients have achieved a complete response. CONCLUSION: A 25% response rate in patients with refractory ovarian cancer was observed, which was durable to six cycles.
OBJECTIVE: Our aim was to determine the efficacy and toxicity of paclitaxel in the treatment of refractory and platinum-resistant epithelial ovarian cancer. STUDY DESIGN: Eligibility required three prior failed chemotherapy regimens and documented platinum resistance. One hundred patients with advanced ovarian cancer received paclitaxel 135 mg/m2 over 24 hours every 21 days with optional granulocyte colony-stimulating factor support. RESULTS:Paclitaxel was generally well tolerated. In four patientsbowel perforation or fistula developed. After three cycles 34% of patients had stable disease and 25% of patients demonstrated a response, either partial or complete. After six cycles 24% of patients continued to respond. To date, six patients have achieved a complete response. CONCLUSION: A 25% response rate in patients with refractory ovarian cancer was observed, which was durable to six cycles.
Authors: M Adams; A H Calvert; J Carmichael; P I Clark; R E Coleman; H M Earl; C J Gallagher; T S Ganesan; M E Gore; J D Graham; P G Harper; G C Jayson; S B Kaye; J A Ledermann; R J Osborne; T J Perren; C J Poole; J A Radford; G J Rustin; M L Slevin; J F Smyth; H Thomas; P M Wilkinson Journal: Br J Cancer Date: 1998-12 Impact factor: 7.640
Authors: M E Gore; G Rustin; M Slevin; C Gallagher; R Penson; R Osborne; J Ledermann; T Cameron; J M Thompson Journal: Br J Cancer Date: 1997 Impact factor: 7.640